Quarterly Activities/Appendix 4C Cash Flow Report

Oct 29, 2026 at 2:13 AM EDT · Issued by Chimeric Therapeutics Limited via ASX

Filed with ASX · Oct 29, 2026 at 2:13 AM EDT

On 6ix: 6ix.com/news/quarterly-activitiesappendix-4c-cash-flow-report-514

APPENDIX 4C Quarter Ended 30 September 2026 Chimeric Therapeutics Limited ACN 638 835 828 ASX: CHM ` ASX ANNOUNCEMENT 29 October 2026 QUARTERLY ACTIVITIES & CASHFLOW REPORT QUARTER ENDING 30 SEPTEMBER 2026 Sydney, Australia, 29 October 2026: Chimeric Therapeutics Limited (ASX: CHM, "Chimeric" or...

View Attachment

6ix is reading this filing.

Chimeric Therapeutics Limited on 6ix

Earlier from Chimeric Therapeutics

CHM ceases enrolment in Phase 1 trial and Company updateAug 18
Chimeric receives $1.62M advance on FY26 R&D tax incentiveJul 29
CHM CDH17 Phase 1 clinical trial update - New DL 3 dataJul 15
Appointment of Financial Adviser for Strategic ReviewJun 30
CHM announces positive Phase 1/2 data at ASCOMay 31

All Chimeric Therapeutics news releases

Follow Chimeric Therapeutics into a list and get an email when it puts out news.

Follow Chimeric Therapeutics